ReviewCritical care (London, England)2014
Septic acute kidney injury: molecular mechanisms and the importance of stratification and targeting therapy.
Review in Critical care (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02530359 (Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury), which is not on this map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Research landscape and emerging themes of ferroptosis in sepsis-associated acute kidney injury: a bibliometric and science-mapping analysis (2016-2025).Frontiers in pharmacology · 2026Pooled it
- The efficacy of renal replacement therapy strategies for septic-acute kidney injury: A PRISMA-compliant network meta-analysis.Medicine · 2019Pooled it
- Functional Role of ALKBH5 in Kidney Injury: Insights Into Mechanisms and Therapeutic Potential.Journal of cellular biochemistry · 2026Review
- Article
- Machine learning model for predicting the risk of AKI in early hemodynamically stable sepsis patients: a study based on the MIMIC IV database.Frontiers in medicine · 2026Article
- Geographic and demographic disparities in sepsis and renal failure mortality: a CDC WONDER-based narrative review of 1999-2020 trends.Annals of medicine and surgery (2012) · 2026Review
- From glycemic variability to digital signal biomarker: a prognostic and precision medicine framework for sepsis-associated acute kidney injury.Renal failure · 2025Article
- Interplay between gut microbiota and acute kidney injury: a review of their mutual influence and causation.Renal failure · 2025Review
- Acute Kidney Injury During Sepsis and Prognostic Role of Coexistent Chronic Heart Failure.Journal of clinical medicine · 2025Review
- Risk factors of acute kidney injury, septic shock and acute respiratory distress syndrome in patients with blood culture‑positive sepsis.Experimental and therapeutic medicine · 2025Article
- Neutrophil and neutrophil extracellular traps in acute kidney injury: from mechanisms to treatments.Frontiers in immunology · 2025Review
- Vitamin C improves 28-day survival in patients with sepsis-associated acute kidney injury in the intensive care unit: a retrospective study.Frontiers in nutrition · 2025Article
- Stage prediction of acute kidney injury in sepsis patients using explainable machine learning approaches.Frontiers in medicine · 2025Article
- Acute Kidney Injury in Sepsis.International journal of molecular sciences · 2024Review
- STING contributes to lipopolysaccharide-induced tubular cell inflammation and pyroptosis by activating endoplasmic reticulum stress in acute kidney injury.Cell death & disease · 2024Article
- Anisodamine (654-1/654-2) ameliorates septic kidney injury in rats by inhibiting inflammation and apoptosis.Frontiers in pharmacology · 2024Article
- Predictive value of miR-582-5p for onset of sepsis-induced acute kidney injury and its functional role during disease development.Central-European journal of immunology · 2024Article
- Predictive Value of the Systemic Immune-Inflammation Index in the 28-Day Mortality for Patients with Sepsis-Associated Acute Kidney Injury and Construction of a Prediction Model.Journal of inflammation research · 2024Article
- Effect of propofol versus midazolam on short-term outcomes in patients with sepsis-associated acute kidney injury.Frontiers in medicine · 2024Article
- Elevated Activated Partial Thromboplastin Time as a Predictor of 28-Day Mortality in Sepsis-Associated Acute Kidney Injury: A Retrospective Cohort Analysis.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The most common cause of acute kidney injury (AKI) in hospitalized patients is sepsis. However, the molecular pathways and mechanisms that mediate septic AKI are not well defined. Experiments performed over the past 20 years suggest that there are profound differences in the pathogenesis between septic and ischemic AKI. Septic AKI often occurs independently of hypoperfusion, and is mediated by a concomitant pro- and anti-inflammatory state that is activated in response to various pathogen-associated molecular patterns, such as endotoxin, as well as damage-associated molecular patterns. These molecular patterns are recognized by Toll-like receptors (TLRs) found in the kidney, and effectuate downstream inflammatory pathways. Additionally, apoptosis has been proposed to play a role in the pathogenesis of septic AKI. However, targeted therapies designed to mitigate the above aspects of the inflammatory state, TLR-related pathways, and apoptosis have failed to show significant clinical benefit. This failure is likely due to the protean nature of septic AKI, whereby different patients present at different points along the immunologic spectrum. While one patient may benefit from targeted therapy at one end of the spectrum, another patient at the other end may be harmed by the same therapy. We propose that a next important step in septic AKI research will be to identify where patients lie on the immunologic spectrum in order to appropriately target therapies at the inflammatory cascade, TLRs, and possibly apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.